[go: up one dir, main page]

AR116939A1 - 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 - Google Patents

2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8

Info

Publication number
AR116939A1
AR116939A1 ARP190103169A ARP190103169A AR116939A1 AR 116939 A1 AR116939 A1 AR 116939A1 AR P190103169 A ARP190103169 A AR P190103169A AR P190103169 A ARP190103169 A AR P190103169A AR 116939 A1 AR116939 A1 AR 116939A1
Authority
AR
Argentina
Prior art keywords
6alkyl
heteroaryl
aryl
6alkenyl
group
Prior art date
Application number
ARP190103169A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR116939A1 publication Critical patent/AR116939A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de nicotinamida como inhibidores de la actividad de los canales de sodio Naᵛ1.8, composiciones farmacéuticas que los comprenden y su uso en el tratamiento o prevención del dolor, tales como el dolor agudo, dolor neuropático, dolor inflamatorio y trastornos de picazón aguda y crónica. Reivindicación 1: Un compuesto de la fórmula estructural [1], o una sal farmacéuticamente aceptable del mismo, en donde A es heteroarilo o heteroarilo fusionado con un anillo de 5 ó 6 miembros saturado o insaturado que contiene 0 - 3 heteroátomos seleccionados independientemente de O, S y N(Rʰ)q, en donde cada heteroarilo, anillo de 5 miembros y anillo de 6 miembros no está sustituido o está sustituido con uno a cinco sustituyentes seleccionados de Rᵃ; B es heteroarilo, en donde el heteroarilo no está sustituido o está sustituido con uno a tres sustituyentes seleccionados de Rᵇ; R¹ se selecciona del grupo que consiste en: (1) hidrógeno, (2) -SO₃H, (3) -SO₂NH₂, (4) -SO₂NRᵉC₁₋₆alquilo, (5) -SO₂NRᵉC(O)C₁₋₆alquilo, (6) -SO₂NRᵉC₂₋₆alquenilo, (7) -SO₂NRᵉC₃₋₆cicloalquilo, (8) -SO₂NRᵉC(O)C₃₋₆cicloalquilo, (9) -SO₂NRᵉC₂₋₆cicloheteroalquilo, (10) -SO₂NRᵉC(O)C₂₋₆cicloheteroalquilo, (11) -SO₂NRᵉ-arilo, (12) -SO₂NRᵉ-heteroarilo, (13) SO₂C₁₋₆alquilo, (14) -SO₂C₁₋₆alquenilo, (15) -SO₂C₃₋₆cicloalquilo, (16) -SO₂C₂₋₆cicloheteroalquilo, (17) -SO₂arilo, (18) -SO₂heteroarilo, (19) -S(O)Rʲ, (20) -SRʲ, (21) -C(O)NH₂, (22) -C(O)NRᵉRʲ, (23) -CO₂H, (24) -CO₂Rʲ, (25) -C(O)Rʲ, (26) -CN, (27) CF₃, (28) halógeno, (29) -OH, (30) -OC₁₋₆alquilo, (31) -OC₂₋₆alquenilo, (32) -OC₃₋₆cicloalquilo, (33) -OC₂₋₆cicloheteroalquilo, (34) -O-arilo, (35) -O-heteroarilo, (36) -OC(O)Rʲ, (37) -OC(O)NRᵉRʲ, (38) -OC(O)N(Rʲ)₂, (39) -C₁₋₆alquilo, (40) -C₂₋₆alquenilo, (41) -C₁₋₆cicloalquilo, (42) -C₂₋₆cicloheteroalquilo, (43) arilo, (44) heteroarilo, (45) -(CH₂)ₙNRᵉC(O)Rʲ, (46) -(CH₂)ₙNRᵉC(O)ORʲ, (47) -(CH₂)ₙNRᵉC(O)N(Rᵉ)₂, (48) -(CH₂)ₙNRᵉC(O)NRᵉRʲ, (49) -(CH₂)ₙNRᵉC(O)N(Rʲ)₂, (50) -(CH₂)ₙNRᵉS(O)ₘRʲ, (51) -(CH₂)ₙNRᵉS(O)ₘN(Rᵉ)₂, (52) -(CH₂)ₙNRᵉS(O)ₘNRᵉRʲ, (53) -(CH₂)ₙNRᵉS(O)ₘN(Rʲ)₂, y (54) -(CH₂)ₙNRᵉRʲ, en donde cada CH₂, alquilo, alquenilo, cicloalquilo, cicloheteroalquilo, arilo y heteroarilo no está sustituido o está sustituido con uno a cuatro sustituyentes seleccionados de Rᵈ; R² se selecciona del grupo que consiste en: (1) hidrógeno, y (2) -C₁₋₆alquilo; R³ se selecciona del grupo que consiste en: (1) un anillo de C₃₋₁₂cicloalquilo monocíclico, bicíclico o espirocíclico, y (2) un anillo de C₂₋₁₂cicloheteroalquilo monocíclico, bicíclico o espirocíclico, en donde el cicloheteroalquilo contiene 1 - 4 heteroátomos seleccionados independientemente de N(Rᵐ)ʳ, O y S, en donde cada anillo de cicloalquilo y cada anillo de cicloheteroalquilo se pueden fusionar con un arilo o heteroarilo, y en donde cada cicloalquilo, cicloheteroalquilo, arilo y heteroarilo no está sustituido o está sustituido con uno a ocho sustituyentes seleccionados de Rᶜ; cada Rᵃ se selecciona del grupo que consiste en: (1) -C₁₋₆alquilo, (2) -OC₁₋₆alquilo, (3) halógeno, (4) -OH, (5) oxo, (6) -CN, (7) -C₃₋₆cicloalquilo, y (8) -C₂₋₅cicloheteroalquilo, en donde cada alquilo, cicloalquilo y cicloheteroalquilo no está sustituido o está sustituido con uno a seis sustituyentes seleccionados de halógeno, OH, NH₂, NH(C₁₋₆alquilo) y N(C₁₋₆alquilo)₂; cada Rᵇ se selecciona independientemente del grupo que consiste en: (1) -CF₃, (2) -CF₂CF₃, (3) -CHF₂, (4) -OCHF₂, (5) -OCH₂CF₃, (6) -OCF₃, (7) CN, (8) halógeno, (9) -Si(C₁₋₆alquilo)₃, (10) -C₁₋₆alquil-O-Rᵏ, (11) -C₁₋₆alquilo, (12) -C₂₋₆alquenilo, (13) -C₂₋₆alquinilo, (14) -C₃₋₆cicloalquilo, (15) -C₂₋₆cicloheteroalquilo, (16) arilo, (17) heteroarilo, (18) -C₁₋₆alquil-C₃₋₆cicloalquilo, (19) -C₁₋₆alquil-C₂₋₆cicloheteroalquilo, (20) -C₁₋₆alquil-arilo, (21) -C₁₋₆alquil-heteroarilo, (22) C₂₋₆alquenil-C₃₋₆cicloalquilo, (23) -C₂₋₆alquenil-C₂₋₆cicloheteroalquilo, (24) -C₂₋₆alquenil-arilo, (25) -C₂₋₆alquenil-heteroarilo, (26) -C₂₋₆alquinil-C₃₋₆cicloalquilo, (27) -C₂₋₆alquinil-cicloheteroalquilo, (28) -C₂₋₆alquinil-arilo, (29) -C₂₋₆alquinil-heteroarilo, (30) NO₂, (31) -OH, (32) -(CH₂)ₚ-OC₁₋₆alquilo, (33) -(CH₂)ₚ-OC₂₋₆alquenilo, (34) -(CH₂)ₚ-OC₂₋₆alquinilo, (35) -(CH₂)ₚ-OC₃₋₆cicloalquilo, (36) -(CH₂)ₚ-OC₂₋₆heterocicloalquilo, (37) -(CH₂)ₚ-O-arilo, (38) -(CH₂)ₚ-O-heteroarilo, (39) -OC₁₋₆alquil-C₃₋₆cicloalquilo, (40) -OC₁₋₆alquil-C₂₋₆heterocicloalquilo, (41) -OC₁₋₆alquil-arilo, (42) -OC₁₋₆alquil-heteroarilo, (1) -S(O)ₘRᵏ, (43) -C₁₋₆alquil-S(O)ₘRᵏ, (44) -C(O)Rᵏ, (45) -N(Rⁱ)₂, y (46) -NRⁱRᵏ, en donde cada Rᵇ no está sustituido o está sustituido con uno a cinco sustituyentes seleccionados de Rᶠ; cada Rᶜ se selecciona independientemente del grupo que consiste en: (1) -CF₃, (2) -CH₂CF₃, (3) -CHF₂, (4) -OCHF₂, (5) -OCF₃, (6) CN, (7) oxo, (8) -OH, (9) halógeno, (10) -C₁₋₆alquilo, (11) -C₂₋₆alquenilo, (12) -C₂₋₆alquinilo, (13) -C₃₋₆cicloalquilo, (14) -C₂₋₆cicloheteroalquilo, (15) -C₁₋₆alquil-C₃₋₆cicloalquilo, (16) -C₁₋₆alquil-C₂₋₆cicloheteroalquilo, (17) -C₁₋₆alquil-arilo, (18) -C₁₋₆alquil-heteroarilo, (19) -C₁₋₆alquenil-C₃₋₆cicloalquilo, (20) -C₁₋₆alquenil-arilo, (21) -C₁₋₆alquenil-heteroarilo, (22) -C₁₋₆alquenil-C₂₋₆cicloheteroalquilo, (23) -C₂₋₆alquinil-C₃₋₆cicloalquilo, (24) -C₂₋₆alquinil-C₂₋₆cicloheteroalquilo, (25) -C₂₋₆alquinil-arilo, (26) -C₂₋₆alquinil-heteroarilo, (27) -OC₁₋₆alquilo, (28) -OC₂₋₆alquenilo, (29) -OC₂₋₆alquinilo, (30) -OC₃₋₆cicloalquilo, (31) -OC₂₋₆heterocicloalquilo, (32) -O-arilo, (33) -O-heteroarilo, (34) -OC₁₋₆alquil-cicloalquilo, (35) -OC₁₋₆alquil-cicloheteroalquilo, (36) -OC₁₋₆alquil-arilo, (37) -OC₁₋₆alquil-heteroarilo, (38) -S(O)ₘRL, (39) -S(O)RL, (40) -S-RL, (41) -C₁₋₆alquil-S(O)ₘRL, (42) -C(O)RL, (43) -C(O)C₁₋₆alquil-RL, (44) -OC(O)RL, (45) -CO₂RL, (46) arilo, y (47) heteroarilo, en donde cada Rᶜ no está sustituido o está sustituido con uno a cinco sustituyentes seleccionados de Rᵍ; Rᵈ se selecciona independientemente del grupo que consiste en: (1) hidrógeno, (2) halógeno, (3) OH, (4) oxo, (5) -C₁₋₆alquilo, (6) -OC₁₋₆alquilo, (7) NH₂, (8) NH(C₁₋₆alquilo), y (9) N(C₁₋₆alquilo)₂; cada Rᵉ se selecciona independientemente del grupo que consiste en: (1) hidrógeno, y (2) -C₁₋₆alquilo; cada Rᶠ se selecciona del grupo que consiste en: (1) halógeno, F, (2) -C₁₋₆alquilo, (3) -OH, (4) -OC₁₋₆alquilo, (5) -OC₃₋₆cicloalquilo, (6) -OC₂₋₆cicloheteroalquilo, (7) CN, (8) -NH₂, (9) -NH(C₁₋₆alquilo), (10) -NH(C₃₋₆cicloalquilo), (11) -NH(C₂₋₆cicloheteroalquilo), (12) -N(C₁₋₆alquilo)₂, (13) -N(C₃₋₆cicloalquilo)₂, y (14) -N(C₂₋₆cicloheteroalquilo)₂, en donde cada alquilo, cicloalquilo y cicloheteroalquilo no está sustituido o está sustituido con uno a tres sustituyentes seleccionados independientemente de: -OH, halógeno, ciano y -S(O)₂CH₃; cada Rᵍ se selecciona del grupo que consiste en: (1) halógeno, (2) C₁₋₆alquilo, (3) -OH, (4) -OC₁₋₆alquilo, (5) -S(O)ₘ-C₁₋₆alquilo, (6) -CN, (7) -CF₃, (8) -OCHF₂, y (9) -OCF₃, en donde cada alquilo no está sustituido o está sustituido con uno a tres sustituyentes seleccionados independientemente de: -OH, halógeno, ciano y -S(O)₂CH₃; cada Rʰ se selecciona independientemente del grupo que consiste en: (1) hidrógeno, y (2) -C₁₋₆alquilo; cada Rⁱ se selecciona independientemente del grupo que consiste en: (1) hidrógeno, y (2) -C₁₋₆alquilo; cada Rʲ se selecciona del grupo que consiste en: (1) -C₁₋₆alquilo, (2) -C₂₋₆alquenilo, (3) -C₃₋₆cicloalquilo, (4) -C₂₋₆cicloheteroalquilo, (5) arilo, y (6) heteroarilo, en donde cada alquilo, alquenilo, cicloalquilo, cicloheteroalquilo, arilo y heteroarilo no está sustituido o está sustituido con uno a tres sustituyentes seleccionados independientemente de: -C₁₋₆alquilo, -C₃₋₆cicloalquilo, -OH, -OC₁₋₆alquilo, -OC₃₋₆cicloalquilo, halógeno, ciano y -S(O)₂CH₃; cada Rᵏ se selecciona del grupo que consiste en: (1) -C₁₋₆alquilo, (2) -C₂₋₆alquenilo, (3) -C₃₋₆cicloalquilo, (4) -C₃₋₆cicloalquilo, (5) -C₂₋₆cicloheteroalquilo, (6) arilo, y (7) heteroarilo, en donde cada alquilo, alquenilo, cicloalquilo, cicloheteroalquilo, arilo y heteroarilo no está sustituido o está sustituido con uno a tres sustituyentes seleccionados independientemente de: -C₁₋₆alquilo, -C₃₋₆cicloalquilo, -OH, -OC₁₋₆alquilo, -OC₃₋₆cicloalquilo, halógeno, ciano y - S(O)₂CH₃; cada RL se selecciona del grupo que consiste en: (1) -C₁₋₆alquilo, (2) -C₂₋₆alquenilo, (3) -C₃₋₆cicloalquilo, (4) -C₂₋₆cicloheteroalquilo, (5) arilo, y (6) heteroarilo, en donde cada alquilo, alquenilo, cicloalquilo, cicloheteroalquilo, arilo y heteroarilo no está sustituido o está sustituido con uno a tres sustituyentes seleccionados independientemente de: -C₁₋₆alquilo, -C₃₋₆cicloalquilo, -OH, -OC₁₋₆alquilo, -OC₃₋₆cicloalquilo, halógeno, ciano y -S(O)₂CH₃; cada Rᵐ se selecciona independientemente del grupo que consiste en: (1) hidrógeno, y (2) -C₁₋₆alquilo; cada n es independientemente 0, 1, 2, 3 ó 4; cada m es independientemente 0, 1 ó 2; cada p es independientemente 0, 1, 2, 3 ó 4; cada q es independientemente 0 ó 1; y cada r es independientemente 0 ó 1.
ARP190103169A 2018-11-02 2019-10-31 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 AR116939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862754742P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
AR116939A1 true AR116939A1 (es) 2021-06-30

Family

ID=68655658

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103169A AR116939A1 (es) 2018-11-02 2019-10-31 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8

Country Status (27)

Country Link
US (4) US11377438B2 (es)
EP (1) EP3873893A1 (es)
JP (1) JP7288051B2 (es)
KR (3) KR102860523B1 (es)
CN (1) CN113272293B (es)
AR (1) AR116939A1 (es)
AU (2) AU2019372057A1 (es)
BR (2) BR122023020853A2 (es)
CA (1) CA3117927A1 (es)
CL (1) CL2021001078A1 (es)
CO (1) CO2021005553A2 (es)
CR (1) CR20210209A (es)
DO (1) DOP2021000082A (es)
EA (1) EA202191177A1 (es)
EC (1) ECSP21030066A (es)
GE (2) GEP20237568B (es)
IL (1) IL282468A (es)
JO (1) JOP20210097A1 (es)
MA (1) MA54076A (es)
MX (1) MX2021005154A (es)
MY (1) MY197128A (es)
NI (1) NI202100029A (es)
PE (1) PE20211693A1 (es)
SG (1) SG11202104326TA (es)
TW (1) TWI784207B (es)
WO (1) WO2020092667A1 (es)
ZA (1) ZA202102628B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898616B1 (en) * 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
ES2997190T3 (en) 2018-12-20 2025-02-14 Amgen Inc Heteroaryl amides useful as kif18a inhibitors
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
EP4007753B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
AU2020397059A1 (en) 2019-12-06 2022-07-21 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CR20220642A (es) * 2020-06-17 2023-02-15 Merck Sharp & Dohme Llc 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
US12516046B2 (en) * 2020-06-17 2026-01-06 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
EP4174069A4 (en) * 2020-07-03 2024-07-10 Wuhan LL Science and Technology Development Co., Ltd. HETEROCYCLIC COMPOUND AND ASSOCIATED USE
CN114591293A (zh) * 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112457294B (zh) * 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
WO2022235558A1 (en) * 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CA3217565A1 (en) * 2021-05-07 2022-11-10 Ashok Arasappan Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
KR20240017064A (ko) * 2021-06-04 2024-02-06 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
IL308954A (en) 2021-06-04 2024-01-01 Vertex Pharma Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
TW202317520A (zh) 2021-06-15 2023-05-01 德商歌林達有限公司 經取代之吡唑醯胺
EP4361142A4 (en) * 2021-06-25 2025-07-09 Hangzhou Innogate Pharma Co Ltd COMPOUND FOR USE AS A KIF18A INHIBITOR
UY39882A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
WO2023049364A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
US20250154109A1 (en) * 2022-02-04 2025-05-15 Latigo Biotherapeutics, Inc Sodium channel blocking compounds, derivatives thereof, and methods of their use
US20250388543A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
EP4511116A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
CN116947713A (zh) * 2022-04-25 2023-10-27 中国科学院上海药物研究所 并环类化合物及其应用
PE20251183A1 (es) 2022-04-25 2025-04-23 Siteone Therapeutics Inc Inhibidores de amida heterociclica biciclica de sodio activado por voltaje 1.8 (nav 1.8) para el tratamiento del dolor
EP4578852A4 (en) * 2022-08-24 2025-12-17 Jiangsu Hengrui Pharmaceuticals Co Ltd HETEROCYCLIC COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE
JP2025529931A (ja) * 2022-08-28 2025-09-09 シャンハイ ホイルン ファーマシューティカル カンパニー リミテッド ナトリウムチャネル調節剤及びその応用
JP2026501116A (ja) 2022-12-06 2026-01-14 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のための製造方法
EP4385980A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Indazoles as inhibitors of nav1.8
EP4385979A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Multicyclic inhibitors of nav1.8
EP4385984A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Pyridine-n-oxides as inhibitors of nav1.8
AR131345A1 (es) 2022-12-14 2025-03-12 Gruenenthal Gmbh SULFOXIMINAS COMO INHIBIDORES DE NaV1.8
WO2024137984A1 (en) * 2022-12-22 2024-06-27 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
EP4660182A1 (en) 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
AR131658A1 (es) 2023-01-30 2025-04-16 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
AR131690A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
AR131715A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS
WO2024159287A1 (pt) 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
KR20250173577A (ko) * 2023-04-19 2025-12-10 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Nav1.8억제제 및 이의 제조 방법 및 용도
CN121100117A (zh) * 2023-05-16 2025-12-09 浙江海正药业股份有限公司 芳香酰胺类衍生物、其制备方法和其在医药上的应用
WO2024259233A2 (en) * 2023-06-16 2024-12-19 Quantx Biosciences Us, Inc. Fused bicyclic heterocyclic or hetero aryl amide compounds
CN119371405A (zh) * 2023-07-26 2025-01-28 上海闻耐医药科技有限公司 多取代吡咯烷类衍生物、其制备方法及用途
WO2025029890A1 (en) * 2023-08-01 2025-02-06 Latigo Biotherapeutics, Inc. Sodium channel blocking compounds, derivatives thereof, and methods of their use
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025147116A1 (en) * 2024-01-05 2025-07-10 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2026006674A1 (en) 2024-06-28 2026-01-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6431779A (en) * 1987-07-28 1989-02-02 Hokuriku Pharmaceutical Pyrazine derivative
WO2005013914A2 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2006016316A1 (en) 2004-08-11 2006-02-16 Koninklijke Philips Electronics N.V. Conference system with quality information
WO2006050476A2 (en) * 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
US8841483B2 (en) * 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
JP2010116389A (ja) * 2008-10-17 2010-05-27 Bayer Cropscience Ag 殺虫性アリールピロリジン類
MX2010003865A (es) * 2007-10-11 2010-06-01 Vertex Pharma Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
EP2212292B1 (en) 2007-10-11 2012-12-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
WO2010043052A1 (en) * 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2246335A1 (de) * 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
CA2789711C (en) * 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US8703768B2 (en) * 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
CN106478497B (zh) * 2010-10-18 2020-05-08 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
US9656959B2 (en) 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
LT2723710T (lt) * 2011-06-27 2016-10-25 Newron Pharmaceuticals S.P.A. Fluorinti arilalkilaminokarboksamido dariniai
MD20140037A2 (ro) 2011-10-26 2014-08-31 Pfizer Limited Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
TWI601726B (zh) 2012-10-31 2017-10-11 拉夸里亞創藥股份有限公司 吡唑並吡啶衍生物作爲ｔｔｘ－ｓ阻斷劑
TWI659945B (zh) 2013-01-31 2019-05-21 維泰克斯製藥公司 作爲鈉通道調節劑之醯胺
NZ710270A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
MX363456B (es) 2013-06-25 2019-03-25 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal.
MX364155B (es) 2013-07-19 2019-04-12 Vertex Pharma Sulfonamidas como moduladores de canales de sodio.
DK3080134T3 (en) * 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS
ES2896400T3 (es) * 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
JP2017214290A (ja) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物
JP6431779B2 (ja) 2015-01-30 2018-11-28 日立オートモティブシステムズ株式会社 車載制御装置および車載制御装置の製造方法
KR101844984B1 (ko) 2016-05-31 2018-04-03 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
GB201615622D0 (en) * 2016-09-14 2016-10-26 Syngenta Participations Ag Improvements in or relating to organic compounds
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
BR112020000553A2 (pt) * 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio

Also Published As

Publication number Publication date
AU2022287562B2 (en) 2024-08-01
US20210387966A1 (en) 2021-12-16
BR122023020853A2 (pt) 2024-01-16
EP3873893A1 (en) 2021-09-08
MX2021005154A (es) 2021-07-15
US12195445B2 (en) 2025-01-14
MY197128A (en) 2023-05-26
SG11202104326TA (en) 2021-05-28
TWI784207B (zh) 2022-11-21
CL2021001078A1 (es) 2021-10-29
GEAP202315648A (en) 2023-07-25
WO2020092667A8 (en) 2021-05-20
CN113272293B (zh) 2024-06-14
KR102812202B1 (ko) 2025-05-23
DOP2021000082A (es) 2021-07-22
JOP20210097A1 (ar) 2023-01-30
CO2021005553A2 (es) 2021-07-30
ZA202102628B (en) 2023-10-25
CA3117927A1 (en) 2020-05-07
CR20210209A (es) 2021-05-20
IL282468A (en) 2021-05-31
KR20240161227A (ko) 2024-11-12
MA54076A (fr) 2022-02-09
TW202031643A (zh) 2020-09-01
AU2022287562A1 (en) 2023-02-02
KR20240161226A (ko) 2024-11-12
AU2019372057A1 (en) 2021-05-27
BR112021008524A8 (pt) 2023-02-07
KR102860523B1 (ko) 2025-09-16
US11377438B2 (en) 2022-07-05
WO2020092667A1 (en) 2020-05-07
CN113272293A (zh) 2021-08-17
GEP20237568B (en) 2023-11-27
US20220289710A1 (en) 2022-09-15
JP7288051B2 (ja) 2023-06-06
JP2022506146A (ja) 2022-01-17
KR20210086687A (ko) 2021-07-08
PE20211693A1 (es) 2021-09-01
EA202191177A1 (ru) 2021-07-28
US20200140411A1 (en) 2020-05-07
US20250084064A1 (en) 2025-03-13
NI202100029A (es) 2021-08-13
ECSP21030066A (es) 2021-05-31
BR112021008524A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
AR116939A1 (es) 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
AR114972A1 (es) Compuestos
AR121044A1 (es) Inhibidores de egfr
PE20240584A1 (es) Agonistas del receptor de glp-1 y usos de los mismos
AR113299A1 (es) Compuestos de isoindolina
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR111808A1 (es) Derivados de pirimidina como moduladores del receptor de pge2
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR036115A1 (es) Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma
AR090328A1 (es) Pirrolidina-2-carboxamidas sustituidas
AR091176A1 (es) Pirrodilina-2-carboxamidas sustituidas
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
AR078303A1 (es) Sulfonas sustituidas que modulan selectivamente el receptor cb2
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
AR094797A1 (es) Derivados de pirrolotriazina como inhibidores de pi3k
AR111874A1 (es) Derivados de pirimidina
AR115384A1 (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
AR114564A1 (es) DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
AR116906A1 (es) Derivados de heteroarilo bicíclico
AR098723A1 (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR115768A1 (es) Inhibidores bicíclicos de las histona desacetilasas